Merck's Keytruda Regime Approved In Canada For Early Breast Cancer Setting

Comments
Loading...
  • Health Canada has approved Merck & Co Inc MRK Keytruda (pembrolizumab) for adult patients with high-risk early-stage triple-negative breast cancer (TNBC) setting.
  • The approval covers Keytruda combined with chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery.
  • Related: EMA's Advisory Group Backs Approval For Merck's Keytruda In Various Cancer Settings.
  • The nod is based on Phase 3 KEYNOTE-522 trial results, demonstrating a statistically significant improvement in patients' event-free survival (EFS) and pathological complete response (pCR) rate.
  • Keytruda was first approved in Canada in 2015 and currently has cancer indications.
  • Price Action: MRK shares are up 0.07% at $86.97 during the premarket session on Monday's last check.
MRK Logo
MRKMerck & Co Inc
$93.50-1.30%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum21.99
Growth97.84
Quality75.12
Value13.72
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: